|
BRPI0820381A2
(en)
|
|
Pharmaceutical Formulations
|
|
LTC2140867I2
(en)
|
|
Pharmaceutical composition
|
|
CY2018030I2
(en)
|
|
PHARMACEUTICAL FORM 514
|
|
BRPI0721651A2
(en)
|
|
PHARMACEUTICAL COMPOSITION
|
|
DK3492069T3
(en)
|
|
PHARMACEUTICAL COMPOSITIONS INCLUDING IRON-OXY-HYDROXIDE
|
|
DK2073795T3
(en)
|
|
Abuse-safe drug formulation
|
|
BRPI0814188A2
(en)
|
|
FORMULATIONS
|
|
BRPI0920521A2
(en)
|
|
pharmaceutical combination
|
|
NO20075628L
(en)
|
|
Pharmaceutical formulations
|
|
BRPI0715712A2
(en)
|
|
PHARMACEUTICAL COMPOSITION
|
|
DK2120884T3
(en)
|
|
Pharmaceutical composition
|
|
BRPI0719393A2
(en)
|
|
Pharmaceutical Composition
|
|
DK2966175T3
(en)
|
|
PHARMACEUTICAL COMPOSITIONS CONTAINING CORTEXOLON-17-ALPHA-PROPIONATE
|
|
BRPI0921654A2
(en)
|
|
pharmaceutical formulation
|
|
BRPI0716445A2
(en)
|
|
pharmaceutical composition
|
|
BRPI0720234A2
(en)
|
|
PHARMACEUTICAL COMPOSITION
|
|
DK2285413T3
(en)
|
|
Pharmaceutical composition
|
|
PT2209464E
(en)
|
|
ANTIMALARIC PHARMACEUTICAL COMPOSITION
|
|
BRPI0921313A2
(en)
|
|
pharmaceutical composition
|
|
BRPI0820198A2
(en)
|
|
pharmaceutical compositions
|
|
BRPI0817053A2
(en)
|
|
Orlistat Pharmaceutical Formulations
|
|
BRPI0912171A2
(en)
|
|
pharmaceutical composition
|
|
BRPI0912656A2
(en)
|
|
solid pharmaceutical formulation
|
|
BRPI0921301A2
(en)
|
|
pharmaceutical composition
|
|
BRPI0823402A2
(en)
|
|
Olmesartan Pharmaceutical Formulations
|